An experimental treatment for COVID-19 has very good results. The severe patients went home after a few days in the hospital.



[ad_1]

The image of an experimental treatment for COVID-19 has very good results. The severe patients went home after a few days in the hospital.

An experimental treatment for COVID-19 has very good results. The severe patients went home after a few days in the hospital.

After so much bad news, I will give you some good news. An experimental treatment seems to be successful in the fight against COVID 19, reports CNN.

It’s about Remdesivir. Covid-19 patients who received Remdesivir recovered quickly. Most went home in a few days.

The patients selected for the clinical trial had severe respiratory symptoms and fever. However, after the Remdesivir administration, they were able to leave the hospital after less than a week of treatment, reports STAT News, cited by CNN.

“The good news is that most of our patients have already been discharged, which is great.” We only lost two patients, “said Dr. Kathleen Mullane, an infectious disease specialist at the University of Chicago who is conducting the clinical trial.

Studies have shown that the drug can prevent and treat coronaviruses, such as SARS-CoV-2.

There is no approved therapy for Covid-19, but the National Institutes of Health is conducting tests for various medications and other treatments, including remdesivir.

The drug, developed by Gilead Sciences, has been tested against Ebola with little success, but multiple animal studies have shown that the drug can prevent and treat coronaviruses like Covid-19, including SARS (severe acute respiratory syndrome) and MERS. (Middle East). Respiratory Syndrome).

In February, the World Health Organization said remdesivir showed potential against Covid-19, reports CNN.

According to CNN, drug trials are also being conducted at dozens of other clinical centers. Gilead sponsors drug tests on 2,400 patients with severe Covid-19 symptoms at 152 test sites worldwide. It also tests the drug in 1,600 patients with moderate symptoms in 169 hospitals and clinics worldwide.

Gilead said he is awaiting the results of the trial by the end of the month.

Photo: Profimedia

For the most important news of the day, broadcast in real time and presented in an equidistant way, I LIKE our Facebook page!


If you liked the article, follow MEDIAFAX.RO on FACEBOOK »

The content of the www.mediafax.ro website is exclusively for your personal information and use. it is Prohibited republish the content of this site in the absence of a MEDIAFAX agreement. To obtain this agreement, contact us at [email protected].



[ad_2]